Vir Biotechnology (VIR) Total Debt (2019 - 2025)

Name: Vir Biotechnology (VIR) Total Debt (2019 - 2025) | Business Quant
Creator: Business Quant

Vir Biotechnology recorded quarterly Total Debt of $17.5 million in Q1 2025, up 8.97% quarter-over-quarter from $16.1 million in Q4 2024.

Vir Biotechnology's Total Debt history runs 5 years deep, the most recent figure standing at $17.5 million for Q1 2025.

In Q1 2025, Total Debt changed N/A year-over-year to $17.5 million; the TTM figure through Mar 2025 stood at $17.5 million (changed N/A YoY), while the FY2024 annual figure was $16.1 million, changed N/A from the prior year.
Total Debt came in at $17.5 million for Q1 2025 at Vir Biotechnology, up from $16.1 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $68.5 million in Q3 2021 to a low of $16.1 million in Q4 2024.
A 3-year average of $30.5 million and a median of $24.4 million in 2021 frame the typical range for Total Debt.
On a YoY basis, Total Debt climbed as much as 457.45% in 2021 and fell as far as 128.04% in 2021.
Vir Biotechnology's Total Debt stood at $68.5 million in 2021, then sank by 76.55% to $16.1 million in 2024, then increased by 8.97% to $17.5 million in 2025.
According to Business Quant data, Total Debt over the past three periods registered $17.5 million, $16.1 million, and $68.5 million for Q1 2025, Q4 2024, and Q3 2021 respectively.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	319.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	110.96 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	1.99 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Vir Biotechnology	1.33 Bn	1.33 Bn	-	-

Download Data 🔒